Urinary Bladder Neoplasms Clinical Trial
Official title:
A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
This study will test a drug called enfortumab vedotin in participants with a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). This study will also evaluate what the side effects are and if the drug works to treat NMIBC. A side effect is anything a drug does to your body besides treating your disease. In this study enfortumab vedotin will be put into the bladder using a catheter. A catheter is a thin tube that can be put into your bladder.
The study will be comprised of 2 parts. The first part (dose escalation) will find the highest dose of enfortumab vedotin that does not cause unacceptable side effects in participants. The second part (dose expansion) will use the dose found in the first part to test how well the drug works. All participants will receive enfortumab vedotin. Treatment on the study will occur during the induction and maintenance phases, and participants will enter a follow-up period after completion of the maintenance phase. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT02612194 -
LCI-GU-URO-CRI-001: Crizotinib in Patients With c-MET or RON-Positive Metastatic Urothelial Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT02805608 -
uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT02534623 -
Postoperative Quality of Recovery After Transurethral Resection of the Bladder
|
N/A | |
| Recruiting |
NCT02228473 -
Effect of Glycopyrrolate and Atropine on Catheter-Related Bladder Discomfort
|
N/A | |
| Completed |
NCT02778243 -
Sexual Steroids: Relationship Between Serum and Prostatic Tissue Level
|
N/A | |
| Recruiting |
NCT05007106 -
MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005)
|
Phase 2 | |
| Completed |
NCT01688999 -
Cabozantinib for Advanced Urothelial Cancer
|
Phase 2 | |
| Completed |
NCT03219333 -
A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
|
Phase 2 | |
| Recruiting |
NCT05068180 -
Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
|
Phase 4 | |
| Terminated |
NCT02560038 -
Trial of Paclitaxel Plus Gemcitabine and Cisplatin in Bladder Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT02252445 -
Propofol and Sevoflurane for Catheter-Related Bladder Discomfort
|
N/A | |
| Not yet recruiting |
NCT02760953 -
TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
|
N/A | |
| Terminated |
NCT04430036 -
AGEN1884 Plus AGEN2034 Combined With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT06289283 -
Microbiota in Urine and Urothelium Can be a Factor for Induction of Urinary Bladder Cancer. The Study Will Examine Urine and Bladder Cancer Tissues From Male Patients and Urine of Controls Using Whole Genomic Sequencing Techniques and 16S rRNA. The Aim is to Elucidate Role of Microbiota in Bladder
|
||
| Active, not recruiting |
NCT03288545 -
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03661320 -
A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer
|
Phase 3 | |
| Completed |
NCT01478685 -
A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors
|
Phase 1 | |
| Completed |
NCT03404791 -
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
|
Phase 1 | |
| Terminated |
NCT01479348 -
Imaging Study for FdCyd and THU Cancer Treatment
|
Early Phase 1 | |
| Recruiting |
NCT05742867 -
A Study to Evaluate Treatment Preferences for Japanese Participants With Muscle-invasive Urothelial Carcinoma of the Bladder
|